CD274 and neoplasm: PD-1/PD-L1 interactions between immune and tumor cells are known to specifically interfere with anti-tumor immunity and the therapeutic blocking of these immune checkpoints underlies the remarkable benefit observed in a minority of cancer patients receiving immunotherapy.